...
首页> 外文期刊>Molecular Carcinogenesis >A novel tumor suppressor gene RhoBTB2 (DBC2): frequent loss of expression in sporadic breast cancer.
【24h】

A novel tumor suppressor gene RhoBTB2 (DBC2): frequent loss of expression in sporadic breast cancer.

机译:一种新型的抑癌基因RhoBTB2(DBC2):在散发性乳腺癌中频繁丧失表达。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

RhoBTB2 was isolated recently as a tumor suppressor gene from human chromosome 8p21.3. Although RhoBTB2 was found to be frequently lost in breast cancer lines, expression status of RhoBTB2 in sporadic breast cancer tissues and its clinical and prognostic value, however, remain unclear. Tissue samples from breast cancer patients and normal controls and cell samples from cell lines were collected and reverse transcription (RT)-PCR was used to monitor the presence of RhoBTB2 mRNA. The protein expression of RhoBTB2 was detected by immunohistochemical staining. Cumulative survival time was assessed by the Kaplan-Meier method and Cox regression model. We discovered that RhoBTB2 expression was lacking in a breast ductal epithelial carcinoma cell line T-47D but was expressed in other types of tumor cell lines and normal tissues we tested. The results from tissue samples showed that RhoBTB2 was absent in 60% of breast cancers on both the mRNA and protein level. The results from RT-PCR were completely uniform with those from immunohistochemistry. We demonstrated that loss of RhoBTB2 more frequently occurred in postmenopausal patients of age >or=50 yr old and in patients with infiltrating ductal carcinoma of the breast. The prognostic value of RhoBTB2 in breast cancers also be assessed by a long-term follow-up investigation and we found that patients with RhoBTB2-negative breast cancer were linked to poor clinical prognosis. Therefore, the loss of RhoBTB2 expression is a common occurrence in breast cancers and it is an important factor in the development and prognosis of sporadic breast cancer.
机译:RhoBTB2是最近从人染色体8p21.3分离的一种抑癌基因。尽管发现RhoBTB2在乳腺癌细胞系中经常丢失,但是RhoBTB2在散发性乳腺癌组织中的表达状态及其临床和预后价值仍然不清楚。收集来自乳腺癌患者和正常对照的组织样品以及来自细胞系的细胞样品,并使用逆转录(RT)-PCR监测RhoBTB2 mRNA的存在。通过免疫组织化学染色检测RhoBTB2的蛋白表达。累积生存时间通过Kaplan-Meier方法和Cox回归模型进行评估。我们发现,RhoBTB2表达在乳腺导管上皮癌细胞系T-47D中缺乏,但在我们测试的其他类型的肿瘤细胞系和正常组织中表达。组织样本的结果显示,无论是mRNA还是蛋白质水平,RhoBTB2在60%的乳腺癌中都不存在。 RT-PCR的结果与免疫组织化学的结果完全一致。我们证明,RhoBTB2的丢失更经常发生在年龄≥50岁的绝经后患者和乳腺浸润性导管癌患者中。 RhoBTB2在乳腺癌中的预后价值也可以通过长期随访研究来评估,我们发现RhoBTB2阴性乳腺癌患者与不良的临床预后相关。因此,RhoBTB2表达的丧失在乳腺癌中很常见,并且是散发性乳腺癌发展和预后的重要因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号